Mondobiotech Holding AG Company presentation

More documents

Recommendations

Info

mondoBIOTECH’s IP Strategy Orphan Drug Inventions US: not more than 200’000 patients DISEASE = ORPHAN INDICATION DISEASE IS NOT ORPHAN BUT LESS ATTRACTIVE ECONOMIC RETURN MEDICAL NEED EXISTS FOR THE DISEASE No diagnosis, treatment and/or prevention is marketing approved OR Similar in other countries EU: not more than 5 patients In 10’000 The Sponsor attributes to the MPC substantial benefits over approved treatments 32
mondoBIOTECH’s IP Strategy: Two Independent Exclusivity Rights • Our Medicinal Product Candidates (MPCs) are already known peptides, whose properties and mechanisms of actions are described in millions of publications • Many of our MPCs have already been on the market for a different indication or were tested in humans for a different indication • Each of our MPCs is a product platform which can be re-directed for a variety of new indications, in rare diseases and potentially in nonrare diseases PATENT INVENTION Invention object of the patent is: NOVEL Invention object of the patent is: NON-OBVIOUS Invention object of the patent feasible for: INDUSTRIAL APPLICATION Combination or First Medical Use of the peptide or of a combination not yet disclosed in literature Combination or First Medical Use of the peptide or the combination is not obvious for the experts in the field ✔ ok 1 st 2 nd Second Medical Use for one or more diseases of the peptide or of a combination not yet disclosed in literature Second Medical Use for one or more disease of the peptide or of a combination is not obvious for the experts in the field ✔ ok ORPHAN DRUG INVENTION PREVALENCE MEDICAL NEED ORPHAN DRUG DESIGNATION 1 st 2 nd US: not more than 200’000 Patients and/or EU: not more than 5 patients in 10’000 people The disease has a wide prevalence, but it is not attractive in terms of economic return • No diagnostic tool, treatment and/or preventive solution exists • The Sponsor demonstrate that the MPC shows substantial benefits over approved treatments ✔ ok ✔ ok 33
Page 1 and 2: Mondobiotech Holding AG Company pre
Page 3 and 4: mondoBIOTECH at a glance • Headqu
Page 5 and 6: Board of Directors Robert Edward Pa
Page 7 and 8: Our approach to drug discovery •
Page 9 and 10: Introduction to the Search&Match me
Page 11 and 12: The Model • Knowledge from litera
Page 13 and 14: The Search and Match Software Platf
Page 15 and 16: Match • Any path through the know
Page 17 and 18: Match - a multi-technique approach
Page 19 and 20: Bio-Mathematical Technology Platfor
Page 21 and 22: Match - Project DK-0112-01 21
Page 23 and 24: Match - Project DK-1001-01 23
Page 25 and 26: MPC Validation: the mondoBIOTECH Co
Page 27 and 28: Set up of new projects PROJECT SET
Page 29 and 30: Intellectual Property Strategy & Cu
Page 31: mondoBIOTECH’s IP Strategy Two in
Page 35 and 36: Orphan Drug Designations 10 Granted
Page 37 and 38: Why Peptides Peptides characteristi
Page 40 and 41: Diversifying the Risk in Drug Disco
Page 42 and 43: Current Pipeline DasKloster 1000-01
Page 46: Scientific Snapshot Information: DK
Page 49 and 50: Scientific Snapshot Information: DK
Page 51 and 52: Products licensed DasKloster 1001-0
Page 53 and 54: Licensed Products • Aviptadil pla
Page 55: mondoBIOTECH holding AG DasKloster

Mondobiotech Holding AG Company presentation

Create successful ePaper yourself

Delete template?

Save as template?